Equillium, Inc.

As of September 5, 2025, Equillium, Inc. is in a bullish trend with strong indicators, but caution is advised due to a bearish RSI despite a year-to-date return of 100.48%.

As of March 23, 2023, Equillium, Inc. is considered risky and overvalued, with concerning financial metrics and a significant decline in stock performance compared to the S&P 500.

As of March 23, 2023, Equillium, Inc. is considered overvalued and classified as risky due to poor financial metrics, including a negative P/E ratio and significant underperformance compared to the S&P 500.

As of May 1, 2025, Equillium, Inc. has shifted to a bearish technical trend, indicated by bearish MACD, Bollinger Bands, moving averages, and underperformance against the S&P 500.

As of March 2022, the management team of Equillium, Inc. includes Executive Chairman Daniel Bradbury, President and CEO Bruce Steel, and Chief Scientific Officer Stephen Connelly, along with several independent directors.

Equillium, Inc. is a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, with a market cap of $11.79 million and a recent net profit of -$9 million. The company is categorized as a micro-cap and has no dividend yield.

As of Jun 18, Equillium, Inc. has a market capitalization of 11.79 million, categorizing it as a Micro Cap company, with net sales of 30.40 million and a net profit of -13.98 million over the latest four quarters.